Phaseline

Targets › CDKN2A

CDKN2A (Cyclin-dependent kinase inhibitor 2A): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Hematology; next expected readout May 2027.

Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. (UniProt, P42771)

Open in Phaseline: the race on CDKN2A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GCP-Service International WestRVU120 (SEL120)
CDK 8/19 inhibitor
CDKN2APhase 2Low Risk Myelodysplastic SyndromesMay 2027

Conditions

Low Risk Myelodysplastic Syndromes (1)

Modalities

small molecule (1)

Companies

GCP-Service International West (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.